申请人:CONCERT PHARMACEUTICALS INC
公开号:WO2018023009A1
公开(公告)日:2018-02-01
This invention relates to deuterated forms of hexahydro-4,7-methano-1H-isoindole-1,3(2H)-diones, and pharmaceutically acceptable salts thereof. In one aspect, the invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising a compound of this invention, including pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier. This invention also provides the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a compounds that modulates the activity of a receptor selected from the group consisting of central dopamine Type 2 (D2) receptor and serotonin Type 2 (5HT2A) receptor. Some exemplary embodiments include a method of treating a disease or condition selected from schizophrenia and depressive episodes associated with bipolar I disorder, the method comprising the step of administering to a subject in need thereof a pharmaceutically acceptable composition of the present invention.
该发明涉及重氘化的六氢-4,7-甲基-1H-异吲哚-1,3(2H)-二酮及其药用盐。在一个方面,该发明提供了一种化合物的化学式(I):或其药用盐。该发明还提供了包括该发明中的化合物的组合物,包括包含该化合物和药用载体的药物组合物。该发明还提供了在治疗通过给予调节中枢多巴胺2型(D2)受体和5-羟色胺2型(5HT2A)受体活性的化合物的方法中使用这些化合物和组合物。一些示例包括治疗精神分裂症和与I型双相情感障碍相关的抑郁发作的方法,该方法包括向有需要的受试者给予本发明的药用组合物。